Sanofi Strengthens Its Immune System-Focused Pipeline With Around $2 Billion Dren Bio Deal

Sanofi SA (NASDAQ:SNY) on Thursday agreed to acquire Dren Bio Inc.’s DR-0201, a targeted bispecific myeloid cell engager (MCE).

DR-0201 is a CD20-directed bispecific antibody that targets and engages specific tissue-resident and trafficking myeloid cells to induce B-cell depletion via targeted phagocytosis.

Recent early clinical study data in autoimmune diseases suggest that deep B-cell depletion might potentially reset the adaptive immune system, leading to sustained treatment-free remission in patients with refractory B-cell-mediated autoimmune diseases such as lupus.

Also Read: FDA Approves Sanofi’s Merilog As First Rapid-Acting Insulin Biosimilar ...